^
Association details:
Biomarker:ATM mutation
Cancer:Solid Tumor
Drug:Bavencio (avelumab) (PD-L1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Excerpt:
Inclusion Criteria: BRCA1, BRCA2 and/or ATM gene defect.
Trial ID: